CD274 and neoplasm: Notably, in view of PD-L1 expression on the target cells, the anti-PD-L1 treatment was found to be highly effective, not only at inducing tumor shrinkage, but also improving NK cell survival, supporting the expansion of the cytotoxic CD57+ subset, and determining the re-expression of CD16.